title: Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
abstract: Bortezomib-induced peripheral neuropathy (BIPN) often is difficult to manage or reverse once it occurs. Treatment usually involves dose-reduction, interruption, or cessation of therapy, as no other interventions have been proven effective. Oncology nurses must be vigilant and recognize BIPN early to prevent patients from experiencing symptoms and complications that may interfere with their quality of life.
authors.affiliation: Hematology-Bone Marrow Transplant Department in the Abramson Cancer Center, University of Pennsylvania, USA. anne.berkowitz@uphs.upenn.edu
authors.forename: Anne
authors.initials: A
authors.lastname: Berkowitz
authors.forename: Suzanne
authors.initials: S
authors.lastname: Walker
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D003937:Diagnosis, Differential; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D009730:Nursing Assessment; D009859:Oncology Nursing; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000451:nursing / Q000628:therapy; D017410:Practice Guidelines as Topic; D011719:Pyrazines / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib